Molekulargenetische Diagnostik
Praxis Dr. Mato Nagel

Kombinierte familiäre Hyperlipämie mit gestörtem VLDL-Metabolismus

Die kombinierte familiäre Hyperlipämie mit gestörtem VLDL-Metabolismus beinhalted Fettstoffwechselstörungen, bei denen die Mutationen zu einer verzögerten Elimination von VLDL aus dem Plasma führen.

Gliederung

Familiäre kombinierte Hyperlipämie
Kombinierte familiäre Hyperlipämie mit Dysfunktion des Fettgewebes
Kombinierte familiäre Hyperlipämie mit VLDL-Überproduktion
Kombinierte familiäre Hyperlipämie mit gestörtem VLDL-Metabolismus
ANGPTL8
APOA1
APOA4
APOA5
APOC3
CETP
GALNT2
LCAT
LIPC
LIPG
LPL
RXRG
USF1
Kombinierte familiäre Hyperlipämie mit gestörter LDL-Clearance

Referenzen:

1.

DeMattos RB et. al. (2004) ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo.

[^]
2.

Dodart JC et. al. (2005) Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease.

[^]
3.

Schächter F et. al. (1994) Genetic associations with human longevity at the APOE and ACE loci.

[^]
4.

Kadotani H et. al. (2001) Association between apolipoprotein E epsilon4 and sleep-disordered breathing in adults.

[^]
5.

Spirin V et al. (2007) Common single-nucleotide polymorphisms act in concert to affect plasma levels of high-density lipoprotein cholesterol.

[^]
6.

Kathiresan S et. al. (2008) Polymorphisms associated with cholesterol and risk of cardiovascular events.

[^]
7.

Aulchenko YS et. al. (2009) Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.

[^]
8.

Sparkes RS et. al. (1987) Human genes involved in lipolysis of plasma lipoproteins: mapping of loci for lipoprotein lipase to 8p22 and hepatic lipase to 15q21.

[^]
9.

Magoori K et. al. (2003) Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E.

[^]
10.

Greenberg SM et. al. (1995) Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy.

[^]
11.

Nicoll JA et. al. (1996) High frequency of apolipoprotein E epsilon 2 in patients with cerebral hemorrhage due to cerebral amyloid angiopathy.

[^]
12.

Yamada M et. al. (1996) Lack of an association between apolipoprotein E epsilon 4 and cerebral amyloid angiopathy in elderly Japanese.

[^]
13.

Nicoll JA et. al. (1997) High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy.

[^]
14.

Greenberg SM et. al. (1998) Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy.

[^]
15.

O'Donnell HC et. al. (2000) Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage.

[^]
16.

Evans D et. al. (2005) Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia.

[^]
17.

Benlian P et. al. (1996) Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene.

[^]
18.

Kawashiri MA et al. (2005) Long-term course of lipoprotein lipase (LPL) deficiency due to homozygous LPL(Arita) in a patient with recurrent pancreatitis, retained glucose tolerance, and atherosclerosis.

[^]
19.

Henderson HE et al. (1991) Amino acid substitution (Ile194----Thr) in exon 5 of the lipoprotein lipase gene causes lipoprotein lipase deficiency in three unrelated probands. Support for a multicentric origin.

[^]
20.

Emi M et al. (1990) Missense mutation (Gly----Glu188) of human lipoprotein lipase imparting functional deficiency.

[^]
21.

Chen Y et. al. (2008) Variations in DNA elucidate molecular networks that cause disease.

[^]
22.

Feussner G et al. (1996) Unusual xanthomas in a young patient with heterozygous familial hypercholesterolemia and type III hyperlipoproteinemia.

[^]
23.

Henderson HE et. al. (1992) The lipoprotein lipase Gly188----Glu mutation in South Africans of Indian descent: evidence suggesting common origins and an increased frequency.

[^]
24.

Hata A et. al. (1992) Missense mutations in exon 5 of the human lipoprotein lipase gene. Inactivation correlates with loss of dimerization.

[^]
25.

Normand T et. al. (1992) Geographic distribution and genealogy of mutation 207 of the lipoprotein lipase gene in the French Canadian population of Québec.

[^]
26.

Sprecher DL et. al. (1992) Trp64----nonsense mutation in the lipoprotein lipase gene.

[^]
27.

Chimienti G et. al. (1992) A G----C change at the donor splice site of intron 1 causes lipoprotein lipase deficiency in a southern-Italian family.

[^]
28.

Gotoda T et. al. (1992) A newly identified null allelic mutation in the human lipoprotein lipase (LPL) gene of a compound heterozygote with familial LPL deficiency.

[^]
29.

Bergeron J et. al. (1992) Prevalence, geographical distribution and genealogical investigations of mutation 188 of lipoprotein lipase gene in the French Canadian population of Québec.

[^]
30.

Ishimura-Oka K et. al. (1992) A missense mutation (Trp86----Arg) in exon 3 of the lipoprotein lipase gene: a cause of familial chylomicronemia.

[^]
31.

Ma Y et. al. (1992) A missense mutation (Asp250----Asn) in exon 6 of the human lipoprotein lipase gene causes chylomicronemia in patients of different ancestries.

[^]
32.

Heizmann C et. al. (1991) DNA polymorphism haplotypes of the human lipoprotein lipase gene: possible association with high density lipoprotein levels.

[^]
33.

Dichek HL et. al. (1991) Identification of two separate allelic mutations in the lipoprotein lipase gene of a patient with the familial hyperchylomicronemia syndrome.

[^]
34.

Kobayashi J et. al. (1992) A heterozygous mutation (the codon for Ser447----a stop codon) in lipoprotein lipase contributes to a defect in lipid interface recognition in a case with type I hyperlipidemia.

[^]
35.

Takagi A et. al. (1992) Molecular studies on primary lipoprotein lipase (LPL) deficiency. One base deletion (G916) in exon 5 of LPL gene causes no detectable LPL protein due to the absence of LPL mRNA transcript.

[^]
36.

Gotoda T et. al. (1991) Heterogeneous mutations in the human lipoprotein lipase gene in patients with familial lipoprotein lipase deficiency.

[^]
37.

Paulweber B et. al. (1991) Molecular basis of lipoprotein lipase deficiency in two Austrian families with type I hyperlipoproteinemia.

[^]
38.

Faustinella F et. al. (1991) Catalytic triad residue mutation (Asp156----Gly) causing familial lipoprotein lipase deficiency. Co-inheritance with a nonsense mutation (Ser447----Ter) in a Turkish family.

[^]
39.

De Braekeleer M et. al. (1991) Founder effect in familial hyperchylomicronemia among French Canadians of Quebec.

[^]
40.

Monsalve MV et. al. (1990) A missense mutation at codon 188 of the human lipoprotein lipase gene is a frequent cause of lipoprotein lipase deficiency in persons of different ancestries.

[^]
41.

Ameis D et. al. (1991) Familial chylomicronemia (type I hyperlipoproteinemia) due to a single missense mutation in the lipoprotein lipase gene.

[^]
42.

Ma Y et. al. (1991) A mutation in the human lipoprotein lipase gene as the most common cause of familial chylomicronemia in French Canadians.

[^]
43.

Beg OU et. al. (1990) Lipoprotein lipaseBethesda: a single amino acid substitution (Ala-176----Thr) leads to abnormal heparin binding and loss of enzymic activity.

[^]
44.

Hata A et. al. (1990) Compound heterozygote for lipoprotein lipase deficiency: Ser----Thr244 and transition in 3' splice site of intron 2 (AG----AA) in the lipoprotein lipase gene.

[^]
45.

Devlin RH et. al. (1990) Partial gene duplication involving exon-Alu interchange results in lipoprotein lipase deficiency.

[^]
46.

Emi M et. al. (1990) Lipoprotein lipase deficiency resulting from a nonsense mutation in exon 3 of the lipoprotein lipase gene.

[^]
47.

Wilson DE et. al. (1990) Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation.

[^]
48.

Langlois S et. al. (1989) A major insertion accounts for a significant proportion of mutations underlying human lipoprotein lipase deficiency.

[^]
49.

Kirchgessner TG et. al. (1989) Organization of the human lipoprotein lipase gene and evolution of the lipase gene family.

[^]
50.

Deeb SS et. al. (1989) Structure of the human lipoprotein lipase gene.

[^]
51.

Heinzmann C et. al. (1987) RFLP for the human lipoprotein lipase (LPL) gene: HindIII.

[^]
52.

Funke H et. al. (1987) Hind III RFLP in the lipoprotein lipase gene, (LPL).

[^]
53.

Li SR et. al. (1988) Pvu-II RFLP at the human lipoprotein lipase (LPL) gene locus.

[^]
54.

Funke H et. al. (1988) Bst NI (Eco RII) RFLP in the lipoprotein lipase gene (LPL).

[^]
55.

Kirchgessner TG et. al. (1987) The sequence of cDNA encoding lipoprotein lipase. A member of a lipase gene family.

[^]
56.

Wion KL et. al. (1987) Human lipoprotein lipase complementary DNA sequence.

[^]
57.

Wilson DE et. al. (1983) Phenotypic heterogeneity in the extended pedigree of a proband with lipoprotein lipase deficiency.

[^]
58.

Levak-Frank S et. al. (1995) Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice.

[^]
59.

Yang WS et al. (1995) A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity.

[^]
60.

Lo JY et. al. (1995) Lipoprotein lipase: role of intramolecular disulfide bonds in enzyme catalysis.

[^]
61.

Ma Y et. al. (1994) Recurrent missense mutations at the first and second base of codon Arg243 in human lipoprotein lipase in patients of different ancestries.

[^]
62.

Emi M et. al. (1993) Structure, organization, and chromosomal mapping of the human macrophage scavenger receptor gene.

[^]
63.

Kobayashi J et. al. (1993) A missense mutation (Ala334-->Thr) in exon 7 of the lipoprotein lipase gene in a case with type I hyperlipidemia.

[^]
64.

Wood S et. al. (1993) Support for founder effect for two lipoprotein lipase (LPL) gene mutations in French Canadians by analysis of GT microsatellites flanking the LPL gene.

[^]
65.

Pepe G et. al. (1994) A new Italian case of lipoprotein lipase deficiency: a Leu365- > Val change resulting in loss of enzyme activity.

[^]
66.

Haubenwallner S et. al. (1993) A novel missense mutation in the gene for lipoprotein lipase resulting in a highly conservative amino acid substitution (Asp180-->Glu) causes familial chylomicronemia (type I hyperlipoproteinemia).

[^]
67.

Wilson DE et. al. (1993) Mutations in exon 3 of the lipoprotein lipase gene segregating in a family with hypertriglyceridemia, pancreatitis, and non-insulin-dependent diabetes.

[^]
68.

Miesenböck G et. al. (1993) Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities.

[^]
69.

Mattei MG et. al. (1993) Assignment of the human lipoprotein lipase (LPL) gene to chromosome band 8p22.

[^]
70.

Ma Y et. al. (1993) Gene-environment interaction in the conversion of a mild-to-severe phenotype in a patient homozygous for a Ser172-->Cys mutation in the lipoprotein lipase gene.

[^]
71.

Reymer PW et. al. (1995) A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia.

[^]
72.

Buscà R et. al. (1996) The mutation Gly142-->Glu in human lipoprotein lipase produces a missorted protein that is diverted to lysosomes.

[^]
73.

Ginzinger DG et. al. (1996) A mutation in the lipoprotein lipase gene is the molecular basis of chylomicronemia in a colony of domestic cats.

[^]
74.

Weinstock PH et. al. (1995) Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes.

[^]
75.

Benlian P et. al. (1996) Complete paternal isodisomy for chromosome 8 unmasked by lipoprotein lipase deficiency.

[^]
76.

Henderson HE et. al. (1996) A new mutation destroying disulphide bridging in the C-terminal domain of lipoprotein lipase.

[^]
77.

de Bruin TW et. al. (1996) Lipoprotein lipase gene mutations D9N and N291S in four pedigrees with familial combined hyperlipidaemia.

[^]
78.

Wittrup HH et. al. (1997) A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease.

[^]
79.

Mailly F et. al. (1997) Familial lipoprotein lipase (LPL) deficiency: a catalogue of LPL gene mutations identified in 20 patients from the UK, Sweden, and Italy.

[^]
80.

Fisher RM et. al. (1997) Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis.

[^]
81.

Kastelein JJ et. al. (1998) The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease. The Regress Study Group.

[^]
82.

Nickerson DA et. al. (1998) DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene.

[^]
83.

Clark AG et. al. (1998) Haplotype structure and population genetic inferences from nucleotide-sequence variation in human lipoprotein lipase.

[^]
84.

Henderson HE et. al. (1998) Ile225Thr loop mutation in the lipoprotein lipase (LPL) gene is a de novo event.

[^]
85.

Wittrup HH et. al. (1999) Mutations in the lipoprotein lipase gene associated with ischemic heart disease in men. The Copenhagen city heart study.

[^]
86.

Boer JM et. al. (1999) Physical activity modulates the effect of a lipoprotein lipase mutation (D9N) on plasma lipids and lipoproteins.

[^]
87.

Bertolini S et. al. (2000) Pseudodominance of lipoprotein lipase (LPL) deficiency due to a nonsense mutation (Tyr302>Term) in exon 6 of LPL gene in an Italian family from Sardinia (LPL(Olbia)).

[^]
88.

Hoffmann MM et. al. (2000) Type I hyperlipoproteinemia due to a novel loss of function mutation of lipoprotein lipase, Cys(239)-->Trp, associated with recurrent severe pancreatitis.

[^]
89.

Samuels ME et. al. (2001) Identification of a common variant in the lipoprotein lipase gene in a large Utah kindred ascertained for coronary heart disease: the -93G/D9N variant predisposes to low HDL-C/high triglycerides.

[^]
90.

Gilbert B et. al. () Lipoprotein lipase (LPL) deficiency: a new patient homozygote for the preponderant mutation Gly188Glu in the human LPL gene and review of reported mutations: 75 % are clustered in exons 5 and 6.

[^]
91.

Clee SM et. al. (2001) The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease.

[^]
92.

Yagyu H et. al. (2003) Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy.

[^]
93.

Ling C et. al. (2003) Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue.

[^]
94.

Yang W et. al. (2004) Lipoprotein lipase gene is in linkage with blood pressure phenotypes in Chinese pedigrees.

[^]
95.

López-Miranda J et. al. (2004) The influence of lipoprotein lipase gene variation on postprandial lipoprotein metabolism.

[^]
96.

Pruneta-Deloche V et. al. (2005) Combination of circulating antilipoprotein lipase (Anti-LPL) antibody and heterozygous S172 fsX179 mutation of LPL gene leading to chronic hyperchylomicronemia.

[^]
97.

Goodarzi MO et. al. (2005) The 3' untranslated region of the lipoprotein lipase gene: haplotype structure and association with post-heparin plasma lipase activity.

[^]
98.

Wittrup HH et. al. (2006) Combined analysis of six lipoprotein lipase genetic variants on triglycerides, high-density lipoprotein, and ischemic heart disease: cross-sectional, prospective, and case-control studies from the Copenhagen City Heart Study.

[^]
99.

Zhao T et. al. (2006) Hemorheological abnormalities in lipoprotein lipase deficient mice with severe hypertriglyceridemia.

[^]
100.

Frikke-Schmidt R et. al. (2007) Subsets of SNPs define rare genotype classes that predict ischemic heart disease.

[^]
101.

Goodarzi MO et. al. (2007) Haplotypes in the lipoprotein lipase gene influence fasting insulin and discovery of a new risk haplotype.

[^]
102.

Kim MS et. al. (2008) Protein kinase D is a key regulator of cardiomyocyte lipoprotein lipase secretion after diabetes.

[^]
103.

Kim YJ et. al. (2011) Large-scale genome-wide association studies in East Asians identify new genetic loci influencing metabolic traits.

[^]
104.

Davies BS et. al. (2012) Assessing mechanisms of GPIHBP1 and lipoprotein lipase movement across endothelial cells.

[^]
105.

Richardson K et. al. (2013) Gain-of-function lipoprotein lipase variant rs13702 modulates lipid traits through disruption of a microRNA-410 seed site.

[^]
106.

Utermann G et. al. (1980) Genetics of the apolipoprotein E system in man.

[^]
107.

Gregg RE et. al. (1981) Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E.

[^]
108.

Hazzard WR et. al. (1981) Genetic transmission of isoapolipoprotein E phenotypes in a large kindred: relationship to dysbetalipoproteinemia and hyperlipidemia.

[^]
109.

Zannis VI et. al. (1981) Human apolipoprotein E isoprotein subclasses are genetically determined.

[^]
110.

St Clair D et. al. (1995) Apolipoprotein E epsilon 4 allele is a risk factor for familial and sporadic presenile Alzheimer's disease in both homozygote and heterozygote carriers.

[^]
111.

Bennett C et. al. (1995) Evidence that the APOE locus influences rate of disease progression in late onset familial Alzheimer's Disease but is not causative.

[^]
112.

Masliah E et. al. (1995) Neurodegeneration in the central nervous system of apoE-deficient mice.

[^]
113.

Farrer LA et. al. (1995) Allele epsilon 4 of apolipoprotein E shows a dose effect on age at onset of Pick disease.

[^]
114.

Polvikoski T et. al. (1995) Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein.

[^]
115.

Levy-Lahad E et. al. (1995) Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease.

[^]
116.

van Ree JH et. al. (1995) Inactivation of Apoe and Apoc1 by two consecutive rounds of gene targeting: effects on mRNA expression levels of gene cluster members.

[^]
117.

Nicoll JA et. al. (1995) Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury.

[^]
118.

Matsunaga A et. al. (1995) Population frequency of apolipoprotein E5 (Glu3-->Lys) and E7 (Glu244-->Lys, Glu245-->Lys) variants in western Japan.

[^]
119.

Mann WA et. al. (1995) Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu).

[^]
120.

Boisvert WA et. al. (1995) Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation.

[^]
121.

van Gool WA et. al. (1995) A case-control study of apolipoprotein E genotypes in Alzheimer's disease associated with Down's syndrome. Dutch Study Group on Down's Syndrome and Ageing.

[^]
122.

Kashyap VS et. al. (1995) Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors.

[^]
123.

Mui S et. al. (1995) Apolipoprotein E epsilon 4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis.

[^]
124.

Osuntokun BO et. al. (1995) Lack of an association between apolipoprotein E epsilon 4 and Alzheimer's disease in elderly Nigerians.

[^]
125.

Kamboh MI et. al. (1995) APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism.

[^]
126.

Tabaton M et. al. (1995) Apolipoprotein E epsilon 4 allele frequency is not increased in progressive supranuclear palsy.

[^]
127.

Blennow K et. al. (1994) Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease.

[^]
128.

Royston MC et. al. (1994) Apolipoprotein E epsilon 2 allele promotes longevity and protects patients with Down's syndrome from dementia.

[^]
129.

Hyman BT et. al. (1995) Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome).

[^]
130.

Strittmatter WJ et. al. (1995) Apolipoprotein E and Alzheimer disease.

[^]
131.

Lippa CF et. al. (1995) Apolipoprotein E genotype and Lewy body disease.

[^]
132.

de Knijff P et. al. (1994) Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels.

[^]
133.

Bétard C et. al. (1994) Apo E allele frequencies in Alzheimer's disease, Lewy body dementia, Alzheimer's disease with cerebrovascular disease and vascular dementia.

[^]
134.

Linton MF et. al. (1995) Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation.

[^]
135.

Talbot C et. al. (1994) Protection against Alzheimer's disease with apoE epsilon 2.

[^]
136.

Corder EH et. al. (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease.

[^]
137.

Yoshizawa T et. al. (1994) Dose-dependent association of apolipoprotein E allele epsilon 4 with late-onset, sporadic Alzheimer's disease.

[^]
138.

Lucotte G et. al. (1994) Apolipoprotein E-epsilon 4 allele doses in late-onset Alzheimer's disease.

[^]
139.

Kawamata J et. al. (1994) Apolipoprotein E polymorphism in Japanese patients with Alzheimer's disease or vascular dementia.

[^]
140.

Amouyel P et. al. (1994) The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease. The French Research Group on Epidemiology of Human Spongiform Encephalopathies.

[^]
141.

Nalbantoglu J et. al. (1994) Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies.

[^]
142.

Marder K et. al. (1994) The apolipoprotein epsilon 4 allele in Parkinson's disease with and without dementia.

[^]
143.

Sanan DA et. al. (1994) Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3.

[^]
144.

Frisoni GB et. al. (1994) Apolipoprotein E epsilon 4 allele frequency in vascular dementia and Alzheimer's disease.

[^]
145.

Borgaonkar DS et. al. (1993) Linkage of late-onset Alzheimer's disease with apolipoprotein E type 4 on chromosome 19.

[^]
146.

None (1993) Apolipoprotein E and Alzheimer's disease.

[^]
147.

Poirier J et. al. (1993) Apolipoprotein E polymorphism and Alzheimer's disease.

[^]
148.

Saunders AM et. al. (1993) Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases.

[^]
149.

Corder EH et. al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

[^]
150.

Saunders AM et. al. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.

[^]
151.

Strittmatter WJ et. al. (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

[^]
152.

Strittmatter WJ et. al. (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

[^]
153.

van den Maagdenberg AM et. al. (1993) Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia.

[^]
154.

Garlepp MJ et. al. (1995) Apolipoprotein E epsilon 4 in inclusion body myositis.

[^]
155.

Lannfelt L et. al. (1995) Apolipoprotein epsilon 4 allele in Swedish twins and siblings with Alzheimer disease.

[^]
156.

Reiman EM et. al. (1996) Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.

[^]
157.

None (1996) Mouse models of atherosclerosis.

[^]
158.

Tomimoto H et. al. (1995) Immunohistochemical study of apolipoprotein E in human cerebrovascular white matter lesions.

[^]
159.

Myers RH et. al. (1996) Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study.

[^]
160.

Poirier J et. al. (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.

[^]
161.

Blesa R et. al. (1996) High apolipoprotein E epsilon 4 allele frequency in age-related memory decline.

[^]
162.

Tang MX et. al. (1996) Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City.

[^]
163.

Payami H et. al. (1996) Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women.

[^]
164.

Hyman BT et. al. (1996) Apolipoprotein E epsilon4/4 in a neuropathologically normal very elderly individual.

[^]
165.

Egensperger R et. al. (1996) The apolipoprotein E epsilon 4 allele in Parkinson's disease with Alzheimer lesions.

[^]
166.

Slooter AJ et. al. (1996) APOE genotyping in differential diagnosis of Alzheimer's disease.

[^]
167.

Olichney JM et. al. (1996) The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant.

[^]
168.

Kurz A et. al. (1996) Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease.

[^]
169.

Growdon JH et. al. (1996) Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease.

[^]
170.

Asada T et. al. (1996) ApoE epsilon 4 allele and cognitive decline in patients with Alzheimer's disease.

[^]
171.

Harrington CR et. al. (1995) Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia.

[^]
172.

Gerdes LU et. al. (1996) The apolipoprotein E polymorphism in Greenland Inuit in its global perspective.

[^]
173.

Bickeböller H et. al. (1997) Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex.

[^]
174.

Payami H et. al. (1997) A prospective study of cognitive health in the elderly (Oregon Brain Aging Study): effects of family history and apolipoprotein E genotype.

[^]
175.

Oikawa S et al. (1997) Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy.

[^]
176.

Sullivan PM et. al. (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis.

[^]
177.

Houlden H et. al. (1998) ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer's disease families.

[^]
178.

Sullivan PM et. al. (1998) Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2.

[^]
179.

Meyer MR et. al. (1998) APOE genotype predicts when--not whether--one is predisposed to develop Alzheimer disease.

[^]
180.

Friedman G et. al. (1999) Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury.

[^]
181.

Kehoe P et. al. (1999) Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length.

[^]
182.

Holtzman DM et. al. (1999) Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease.

[^]
183.

Wiebusch H et. al. (1999) Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease.

[^]
184.

Teasdale GM et. al. (1997) Association of apolipoprotein E polymorphism with outcome after head injury.

[^]
185.

Matsunaga A et. al. (1999) A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.

[^]
186.

McCarron MO et. al. (1999) APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis.

[^]
187.

Lambert JC et. al. (2000) Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations-the ECTIM study.

[^]
188.

Holtzman DM et. al. (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease.

[^]
189.

Corbo RM et. al. (1999) Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a 'thrifty' allele?

[^]
190.

Raber J et. al. (2000) Apolipoprotein E and cognitive performance.

[^]
191.

Wiggs JL et. al. (2000) Genome-wide scan for adult onset primary open angle glaucoma.

[^]
192.

Yaffe K et. al. (2000) Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction.

[^]
193.

Mitchell C et. al. (2000) Therapeutic liver repopulation in a mouse model of hypercholesterolemia.

[^]
194.

Wang HY et. al. (2000) Apolipoprotein E is a genetic risk factor for fetal iodine deficiency disorder in China.

[^]
195.

Ishigaki Y et. al. (2000) Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice.

[^]
196.

Fullerton SM et. al. (2000) Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism.

[^]
197.

Gerdes LU et. al. (2000) Estimation of apolipoprotein E genotype-specific relative mortality risks from the distribution of genotypes in centenarians and middle-aged men: apolipoprotein E gene is a "frailty gene," not a "longevity gene".

[^]
198.

Tangirala RK et. al. (2001) Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E.

[^]
199.

Salero E et. al. (2001) Transcription factors Zic1 and Zic2 bind and transactivate the apolipoprotein E gene promoter.

[^]
200.

Knouff C et al. (2001) Doubling expression of the low density lipoprotein receptor by truncation of the 3'-untranslated region sequence ameliorates type iii hyperlipoproteinemia in mice expressing the human apoe2 isoform.

[^]
201.

Reynolds WF et. al. (2000) MPO and APOEepsilon4 polymorphisms interact to increase risk for AD in Finnish males.

[^]
202.

Nguyen TT et al. (2000) Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (delta149 Leu)].

[^]
203.

Wang JC et. al. (2000) Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease.

[^]
204.

Frikke-Schmidt R et. al. (2001) APOE genotype predicts AD and other dementia but not ischemic cerebrovascular disease.

[^]
205.

Chapman J et. al. (2001) APOE genotype is a major predictor of long-term progression of disability in MS.

[^]
206.

Bonay P et. al. (2001) Apolipoprotein E4 stimulates sulfation of glycosaminoglycans in neural cells.

[^]
207.

Peskind ER et. al. (2001) Increased CSF cortisol in AD is a function of APOE genotype.

[^]
208.

Anderson DH et. al. (2001) Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation.

[^]
209.

Broderick J et. al. (2001) Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke.

[^]
210.

Ghebremedhin E et. al. (2001) Gender and age modify the association between APOE and AD-related neuropathology.

[^]
211.

Zubenko GS et. al. (2001) D10S1423 identifies a susceptibility locus for Alzheimer's disease in a prospective, longitudinal, double-blind study of asymptomatic individuals.

[^]
212.

Mortensen EL et. al. (2001) A gender difference in the association between APOE genotype and age-related cognitive decline.

[^]
213.

Huang Y et. al. (2001) Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons.

[^]
214.

Lambert JC et. al. (2001) Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer's disease.

[^]
215.

Chen G et. al. (2001) A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion.

[^]
216.

Chapman J et. al. (2001) The effects of APOE genotype on age at onset and progression of neurodegenerative diseases.

[^]
217.

Sass JO et. al. (2001) Increased CSF cortisol in AD is a function of APOE genotype.

[^]
218.

Murray BJ et. al. (2001) Effects of vagus nerve stimulation on respiration during sleep.

[^]
219.

Lesuisse C et. al. (2001) Hyper-expression of human apolipoprotein E4 in astroglia and neurons does not enhance amyloid deposition in transgenic mice.

[^]
220.

Goldstein FC et. al. (2001) Apolipoprotein E and age at onset of Alzheimer's disease in African American patients.

[^]
221.

Bayer AU et. al. (2002) Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease.

[^]
222.

Cohen RM et. al. (2001) Effect of apolipoprotein E genotype on hippocampal volume loss in aging healthy women.

[^]
223.

Zareparsi S et. al. (2002) Age at onset of Parkinson disease and apolipoprotein E genotypes.

[^]
224.

Mori E et. al. (2002) Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele.

[^]
225.

Liberman JN et. al. (2002) Apolipoprotein E epsilon 4 and short-term recovery from predominantly mild brain injury.

[^]
226.

Dal Forno G et. al. (2002) APOE genotype and survival in men and women with Alzheimer's disease.

[^]
227.

Crawford FC et. al. (2002) APOE genotype influences acquisition and recall following traumatic brain injury.

[^]
228.

Scarmeas N et. al. (2002) Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease.

[^]
229.

Copin B et. al. (2002) Apolipoprotein E-promoter single-nucleotide polymorphisms affect the phenotype of primary open-angle glaucoma and demonstrate interaction with the myocilin gene.

[^]
230.

Lambert JC et. al. (2002) Contribution of APOE promoter polymorphisms to Alzheimer's disease risk.

[^]
231.

Verpillat P et. al. (2002) Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis.

[^]
232.

Wilson RS et. al. (2002) The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period.

[^]
233.

Deary IJ et. al. (2002) Cognitive change and the APOE epsilon 4 allele.

[^]
234.

Morrow JA et. al. (2002) Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease.

[^]
235.

Yamauchi T et. al. (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis.

[^]
236.

Garcés C et. al. (2002) Influence of birth weight on the apo E genetic determinants of plasma lipid levels in children.

[^]
237.

Enzinger C et. al. (2003) Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele.

[^]
238.

Bennett DA et. al. (2003) Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease.

[^]
239.

Schultz DW et. al. (2003) Lack of an association of apolipoprotein E gene polymorphisms with familial age-related macular degeneration.

[^]
240.

Ye S et. al. (2003) Independent effects of the -219 G>T and epsilon 2/ epsilon 3/ epsilon 4 polymorphisms in the apolipoprotein E gene on coronary artery disease: the Southampton Atherosclerosis Study.

[^]
241.

Bunce C et. al. (2003) Single-nucleotide polymorphisms and glaucoma severity.

[^]
242.

Matsumoto S et. al. (2003) Modulation of the onset age in primary dystonia by APOE genotype.

[^]
243.

Pastor P et. al. (2003) Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred.

[^]
244.

Infante-Rivard C et. al. (2003) Small babies receive the cardiovascular protective apolipoprotein epsilon 2 allele less frequently than expected.

[^]
245.

Harris FM et. al. (2003) Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice.

[^]
246.

Qiu C et. al. (2003) Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD.

[^]
247.

Novaro GM et. al. (2003) Association between apolipoprotein E alleles and calcific valvular heart disease.

[^]
248.

Long JR et. al. (2003) APOE and TGF-beta1 genes are associated with obesity phenotypes.

[^]
249.

Ressiniotis T et. al. (2004) The role of apolipoprotein E gene polymorphisms in primary open-angle glaucoma.

[^]
250.

Kantarci OH et. al. (2004) Association of APOE polymorphisms with disease severity in MS is limited to women.

[^]
251.

Enzinger C et. al. (2004) Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-epsilon 4.

[^]
252.

De Stefano N et. al. (2004) Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis.

[^]
253.

Lund G et. al. (2004) DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E.

[^]
254.

Tiraboschi P et. al. (2004) Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease.

[^]
255.

Caselli RJ et. al. (2004) Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele.

[^]
256.

Li YJ et. al. (2004) Apolipoprotein E controls the risk and age at onset of Parkinson disease.

[^]
257.

Prince JA et. al. (2004) APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42.

[^]
258.

Huang X et. al. (2004) APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease.

[^]
259.

Witsch-Baumgartner M et. al. (2004) Maternal apo E genotype is a modifier of the Smith-Lemli-Opitz syndrome.

[^]
260.

Gottlieb DJ et. al. (2004) APOE epsilon4 is associated with obstructive sleep apnea/hypopnea: the Sleep Heart Health Study.

[^]
261.

Koponen S et. al. (2004) APOE-epsilon4 predicts dementia but not other psychiatric disorders after traumatic brain injury.

[^]
262.

Bray NJ et. al. (2004) Allelic expression of APOE in human brain: effects of epsilon status and promoter haplotypes.

[^]
263.

Zwemmer J et. al. (2004) Association of APOE polymorphisms with disease severity in MS is limited to women.

[^]
264.

Farlow MR et. al. (2004) Impact of APOE in mild cognitive impairment.

[^]
265.

Ricci R et. al. (2004) Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis.

[^]
266.

Huang W et. al. (2004) APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study.

[^]
267.

Blair CK et. al. (2005) APOE genotype and cognitive decline in a middle-aged cohort.

[^]
268.

Tsuang DW et. al. (2005) Genetic association between the APOE*4 allele and Lewy bodies in Alzheimer disease.

[^]
269.

Steffens S et. al. (2005) Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.

[^]
270.

Dufouil C et. al. (2005) APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study.

[^]
271.

Devanand DP et. al. (2005) Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.

[^]
272.

Malek G et. al. (2005) Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration.

[^]
273.

Seitz A et. al. (2005) Sense and antisense transcripts of the apolipoprotein E gene in normal and ApoE knockout mice, their expression after spinal cord injury and corresponding human transcripts.

[^]
274.

Faivre L et al. (2005) Variable expressivity of the clinical and biochemical phenotype associated with the apolipoprotein E p.Leu149del mutation.

[^]
275.

O'Hara R et. al. (2005) Nocturnal sleep apnea/hypopnea is associated with lower memory performance in APOE epsilon4 carriers.

[^]
276.

van den Elzen P et. al. (2005) Apolipoprotein-mediated pathways of lipid antigen presentation.

[^]
277.

Gureje O et. al. (2006) APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians.

[^]
278.

Price DA et. al. (2006) Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection.

[^]
279.

Ye S et. al. (2005) Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target.

[^]
280.

Chang S et. al. (2005) Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity.

[^]
281.

Babiloni C et. al. (2006) Apolipoprotein E and alpha brain rhythms in mild cognitive impairment: a multicentric electroencephalogram study.

[^]
282.

Acciarri A et. al. (2006) Apoe epsilon2-epsilon4 genotype is a possible risk factor for primary progressive aphasia.

[^]
283.

Baird PN et. al. (2006) Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD).

[^]
284.

Christensen K et. al. (2006) The quest for genetic determinants of human longevity: challenges and insights.

[^]
285.

Peskind ER et. al. (2006) Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition.

[^]
286.

van der Flier WM et. al. (2006) The effect of APOE genotype on clinical phenotype in Alzheimer disease.

[^]
287.

Wang JM et. al. (2006) Activation of estrogen receptor alpha increases and estrogen receptor beta decreases apolipoprotein E expression in hippocampus in vitro and in vivo.

[^]
288.

Busch RM et. al. (2007) ApoE-epsilon4 is associated with reduced memory in long-standing intractable temporal lobe epilepsy.

[^]
289.

Koutsis G et. al. (2007) APOE epsilon4 is associated with impaired verbal learning in patients with MS.

[^]
290.

Borroni B et. al. (2007) The effect of APOE genotype on clinical phenotype in Alzheimer disease.

[^]
291.

Zetterberg M et. al. (2007) Apolipoprotein E polymorphisms in patients with primary open-angle glaucoma.

[^]
292.

Gozal D et. al. (2007) APOE epsilon 4 allele, cognitive dysfunction, and obstructive sleep apnea in children.

[^]
293.

Lanterna LA et. al. (2007) Meta-analysis of APOE genotype and subarachnoid hemorrhage: clinical outcome and delayed ischemia.

[^]
294.

Rovin BH et al. (2007) APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy.

[^]
295.

Donnelly LA et. al. (2008) Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.

[^]
296.

Burt TD et. al. (2008) Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression.

[^]
297.

Allen NC et. al. (2008) Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database.

[^]
298.

Agosta F et. al. (2009) Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia.

[^]
299.

van Vliet P et. al. (2009) APOE genotype modulates the effect of serum calcium levels on cognitive function in old age.

[^]
300.

Caselli RJ et. al. (2009) Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect.

[^]
301.

van der Walt A et. al. (2009) Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy.

[^]
302.

Ghaffar O et. al. (2010) APOE epsilon4 and the cognitive genetics of multiple sclerosis.

[^]
303.

Bell RD et. al. (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A.

[^]
304.

Dutta P et. al. (2012) Myocardial infarction accelerates atherosclerosis.

[^]
305.

Silva F et. al. (2013) High apolipoprotein E4 allele frequency in FXTAS patients.

[^]
306.

Rhinn H et. al. (2013) Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease.

[^]
307.

Theendakara V et. al. (2013) Neuroprotective Sirtuin ratio reversed by ApoE4.

[^]